Omadacycline: Recently Approved Antimicrobial Agent
Abstract
No abstract.
Disclaimer
The information herein should not be solely relied upon for treatment purposes and medical practitioners are advised to do their own ascertainment before prescribing. The Indian Practitioner, its publishers and editors, and the author, collectively and individually do not take any liability for any consequences whatsoever caused to any person/s by the usage of this drug or information.
References
1. Honeyman, Laura; Ismail, Mohamed; Nelson, Mark L.; Bhatia, Beena; Bowser, Todd E.; Chen, Jackson; Mechiche, Rachid; Ohemeng, Kwasi; Verma, Atul K.; Cannon, E. Pat; MacOne, Ann; Tanaka, S. Ken; Levy, Stuart (2015). “Structure-Activity Relationship of Aminomethylcyclines and the Discovery of Omadacycline.” Anti-microbial Agents and Chemotherapy. 59(11): 7044–7053.
2. Tanaka, S. Ken (20 June 2016). “in vitro and in vivo Assessment of Cardiovascular effects with Omadacycline.”Antimicrobial Agents and Chemotherapy. 60 (9): 5247–53.
3. Villano, Stephen (19 August 2016). “Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections”. Future Microbiology. 11 (11): 1421–1434.
4. Flarakos, Jimmy (8 August 2016). “Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline”. Xenobiotica. 47 (8): 682–696.
5. Paratek announces FDA approval of NUZYRA™ (Omadacycline) [news release]. Boston, MA; October 2, 2018: Paratek. nasdaq.com/press-release/paratek-announces-fda-approval-of-nuzyra-omadacycline-20181002-01269. Accessed October 3, 2018.
2. Tanaka, S. Ken (20 June 2016). “in vitro and in vivo Assessment of Cardiovascular effects with Omadacycline.”Antimicrobial Agents and Chemotherapy. 60 (9): 5247–53.
3. Villano, Stephen (19 August 2016). “Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections”. Future Microbiology. 11 (11): 1421–1434.
4. Flarakos, Jimmy (8 August 2016). “Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline”. Xenobiotica. 47 (8): 682–696.
5. Paratek announces FDA approval of NUZYRA™ (Omadacycline) [news release]. Boston, MA; October 2, 2018: Paratek. nasdaq.com/press-release/paratek-announces-fda-approval-of-nuzyra-omadacycline-20181002-01269. Accessed October 3, 2018.
Published
2019-07-24
How to Cite
Prabhakar Singh. (2019). Omadacycline: Recently Approved Antimicrobial Agent. The Indian Practitioner, 72(7), 54-55. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/395
Section
Drug Profile
